Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 6/20 | 0.41 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C18 | P33260 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 3/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2579843 | 0.91 | RORC (0.43) | RORCTEAD1NR3C1MEN1KMT2A | |
| SCHEMBL2577766 | 0.91 | MCL1 (0.44) | RORCTEAD1NR3C1MCL1BCL2L1 | |
| SCHEMBL7257038 | 0.89 | KEAP1 (0.48) | NR3C1MEN1MAPTKMT2A | |
| SCHEMBL7252238 | 0.88 | MAPT (0.52) | RORCNR3C1MEN1GAAMAPT | |
| SCHEMBL2577609 | 0.83 | RORC (0.43) | ACHERORCCYP2C8CYP2C9CYP2C18 | |
| SCHEMBL7455279 | 0.83 | TEAD1 (0.43) | TEAD1ESR1MEN1MAPTKMT2A | |
| SCHEMBL7255108 | 0.82 | KEAP1 (0.46) | NR3C1MAPT | |
| SCHEMBL7458622 | 0.79 | RORC (0.45) | RORCCYP2C9CYP2C19MCL1BCL2L1 | |
| SCHEMBL7256988 | 0.78 | MCL1 (0.43) | RORCNR3C1MCL1BCL2L1MEN1 | |
| SCHEMBL4853866 | 0.76 | RORC (0.44) | RORCMCL1BCL2L1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191319-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. | 2003-10-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191319-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, ASPH, PREP | ACHE 2422/4885RORC 3583/4885TEAD1 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.